Wild-type p53 demonstrates functional dominance in a human colon carcinoma cell line in which it induces reversible growth arrest

Clinical Cancer Research

Volumn 2, Issue 10, 1996, Pages 1639-1647

  Yang, Bin ^a   Stambrook, Peter J ^b   Markowitz, Sanford D ^a,c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Ireland Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

CELL CYCLE; CELL DIVISION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; GENES, P53; HUMANS; ISOPROPYL THIOGALACTOSIDE; REPRESSOR PROTEINS; TUMOR CELLS, CULTURED;

EID: 0029856928     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Baker, S., Fearon, E., Nigro, J., Hamilton, S., Preisinger, A., Jessup, J., VanTuinen, P., Ledbetter, D., Barker, K., Nakamura, Y., White, R., and Vogelstein, B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (Washington DC), 244: 217-221, 1989.
2. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
3. Levine, A., Momand, J., and Finilay, C. The p53 tumor suppressor gene. Nature (Lond.), 351: 453-456, 1991.
4. Boring, C., Squires, T., Tong, T., and Montgomery, S. Cancer Statistics, 1994. CA Cancer J. Clin., 44: 7-26, 1994.
5. Hinds, P., Finlay, C., Quartin, R , Baker, S., Fearon, E., and Vogelstein, B. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells. a comparison of the "hot spot" mutant phenotypes. Cell Growth & Differ., 1: 571-580, 1990.
6. Chen, P-L., Chen, Y., Bookstein, R., and Lee, W-H. Genetic mechanisms of tumor suppression by the human p53 gene Science (Washington DC), 250. 1576-1580, 1990.
7. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A., Moore, M., Finlay, C., and Levine, A. Gain of function mutations in p53 Nat. Genet., 4: 42-46, 1993.
8. Baker, S., Preisinger, A., Jessup, J., Paraskeva, C., Markowitz, S., Willson, J., Hamilton, S., and Vogelstein, B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res., 50. 7717-7722, 1990.
9. Fields, S., and Jang, S. Presence of a potent transcription activating sequence in the p53 protein. Science (Washington DC). 249: 1046-1048, 1990.
10. Raycroft, L., Wu, H., and Lozano, G. Transcriptional activation by wild-type p53 but not transforming mutant of the p53 anti-oncogene. Science (Washington DC), 249: 1049-1051, 1990.
11. Ullrich, S., Anderson, C., Mercer, W., and Appella, E. The p53 tumor suppressor protein, a modulator of cell proliferation. J. Biol. Chem., 267: 15259-15262, 1992.
12. Zambetti, G., Bargonetti, J., Walker, K., Prives, C., and Levine, A. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev., 6: 1143-1152, 1992.
13. Ramqvist, T., Magnuson, K., Wang, Y., Szekeley, L., and Klein, G. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene, 8: 1495-1500, 1993.
14. Ryan, J., Prochownik, E., Gottlieb, C., Apel, I., Merino, R., Nunez, G., and Clarke, M. C-myc and bcl2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc. Natl. Acad. Sci. USA, 91: 5878-5882, 1994.
15. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Saches, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.
16. Chiou, S-K., Rao, L., and White, E. Bcl-2 blocks p53-dependent apoptosis. Mol. Cell. Biol., 14: 2556-2563, 1994.
17. Symonds, H., Krall, L., Remington, L., Robles-Saenz, M., Lowe, S., Jacks, T., and Van Dyke, T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell, 78: 703-711, 1994.
18. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol., 119: 493-501, 1992.
19. Potten, C., and Allen, T. Ultrastructure of cell loss in intestinal mucosa. J. Ultrastruct. Res., 60: 272-277, 1977.
20. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
21. Hu, M. C-T. Targeting the Escherichia coli lac repressor to the mammalian cell nucleus. Gene (Amst.), 99: 141-150, 1991.
22. Labow, M., Baim, S., Shenk, T., and Levine, A. Conversion of lac repressor into an allosterically regulated transcriptional activator for mammalian cells. Mol. Cell. Biol., 10: 3343-3356, 1990.
23. Liu, H-S., Scrable, H., Villaret, D., Lieberman, M., and Stambrook, P. Control of Ha-ras-mediated mammalian cell transformation by Escherchia coli regulatory elements. Cancer Res., 52: 983-989, 1992
24. Leibovitz, A., Stinson, J., McCombs, W., McCoy, C., Mazur, K., and Mabry, N. Classification of human colorectat adenocarcinoma cell lines. Cancer Res., 36: 4562-4569, 1976.
25. Wigler, M., Pellicer, S., and Axel, R. Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor. Cell, 14. 725-731, 1978.
26. Davis, L., Dibner, M., and Battey, J. Basic Methods in Molecular Biology, pp. 321-323. New York: Elsevier Science Publishing Co., Inc., 1986.
27. Markowitz, S., Haut, M., Stellato, T., Gerbic, C., and Molkentin, K. Exprssion of the erbA-β class of thyroid hormone receptors is selectively lost in human colon carcinoma. J. Clin. Invest., 84: 1683-1687, 1989.
28. Dolbeare, F., Gratzner, H., Pallavicim, M., and Gray, J. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc. Natl. Acad. Sci. USA, 80: 5573-5577, 1983.
29. Gannon, J. V., Greaves, R., Iggo, R., and Lane, D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J., 9: 1595-1602, 1990.
30. Lu, X., Park, S., Thompson, T., and Lane, D. Ras-induced hyper-plasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell, 10: 153-161, 1992.
31. Slingerland, J., and Benchimol, S. Transforming activity of mutant human p53 alleles. J. Cell. Physiol., 148: 391-395, 1991.
32. El-Deiry, W., Tokino, T., Velculescu, V., Levy, D., Parsons, R., Trent, J , Lin, D., Mercer, W., Kinzler, K., and Vogelstein, B. WAF1, a protein mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
33. Sheikh, M., Li, X-S., Chen, J-C, Shao, Z-M , Ordonez, J., and Fontana, J. Mechanism of regulation of WAF1/CIP1 gene expression in human breast carcinoma: role of p53-dependent signal transduction pathways. Oncogene, 9: 3407-3415, 1994.
34. Steinman, R., Hoffman, B., Iro, A., Guillot, C., Lieberman, D., and Houseini, M. Induction of p21 (WAF1/CIP1) during differentiation. Oncogene, 9: 3389-3396, 1994.
35. Milner, J., and Medcalf, E. Cotranslation of activated mutant p53 with wild type drives the wild type p53 protein into mutant conformation. Cell, 65: 765-774, 1991.
36. Kern, S. E., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., and Vogelstein, B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (Washington DC), 256; 827-830, 1992.
37. Goyette, M., Cho, K., Fasching, C., Levy, D., Kinzler, K., Paraskeva, C., Vogelstein, B., and Stanbridge, E. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol. Cell. Biol., 12: 1387-1395, 1992.
38. Forrester, K., Lupold, S. E., Ott, V., Chay, C., Band, V., Wang, X., and Harris, C. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene, 10: 2103-2111, 1995.
39. Merritt, A., Potten, C., Kemp, C., Hickman, J., Balmain, A., Lane, D., and Hall, P. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res., 54: 614-617, 1994.
40. Mercer, W., Shields, M., Amin, M., Sauve, G., Appella, E., Romano, J., and Ullrich, S. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc. Natl. Acad. Sci. USA, 87: 6166-6170, 1990.
41. Shaw, P., Bovey, R., Tardy, S., Sahli, R., Soada, B., and Costa, J. Induction of apoptosis by wild-type p53 in a human colon tumorderived cell line. Proc. Natl. Acad. Sci. USA, 89: 4495-4499, 1992.
42. Harper, J., Adami, G., Wei, N., Keyomarsi, K., and Elledge, S. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 806-816, 1993.
43. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
44. Jiang, H., Lin, J., Su, Z., Collart, F., Huberman, E., and Fisher, P. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene, 9: 3397-3406, 1994
45. Michieli, P., Chedid, M., Lin, D., Pierce, J., Mercer, W., and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
46. WAF1/cIp1 expression in normal and neoplastic tissues. Cancer Res., 55: 2910-2919, 1995.